Learning from the microbes: exploiting the microbiome to enforce T cell immunotherapy.

Area of Science:

• Immunology
• Oncology
• Microbiology

Background:

• Adoptive cellular therapy, particularly chimeric antigen receptor (CAR) T cell therapy, shows promise for hematologic malignancies.
• Mechanisms of treatment resistance and relapse in CAR T cell therapy are not fully understood.
• Host-derived factors, including the microbiome, significantly impact the tumor microenvironment and immunotherapy outcomes.

Purpose of the Study:

• To review recent findings on microbiome-cancer interactions.
• To explore how commensal factors can advance cellular immunotherapy.
• To discuss the role of the microbiome in CAR T cell therapy efficacy and toxicity.

Main Methods:

• Literature review of studies investigating microbiome-cancer interactions.
• Analysis of research on T cell exhaustion and dysfunction in the context of immunotherapy.
• Examination of host-derived factors influencing the immune and tumor microenvironment.

Main Results:

• The microbiome modulates host immunity and the tumor microenvironment, affecting cancer immunotherapy response.
• Microbiota-derived metabolites and microbial composition show potential predictive value for CAR T cell therapy outcomes.
• Diverse mechanisms, including epigenetic, metabolic, and signaling pathways, underlie microbiome effects on immunotherapy.

Conclusions:

• The microbiome is a critical host factor influencing CAR T cell therapy.
• Exploiting microbiome-derived factors offers new strategies to enhance CAR T cell function and efficacy.
• Further research into microbiome-cancer interactions is crucial for advancing cellular immunotherapy.